Off-label use of prescription medications for insomnia: Sedating antidepressants, antipsychotics, anxiolytics, and anticonvulsants

Insomnia: Diagnosis and Treatment

Volumn , Issue , 2016, Pages 397-409

  McCall, W Vaughn ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953656591     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Walsh JK. Drugs used to treat insomnia in 2002: Regulatory-based rather than evidence-based medicine. Sleep 2004; 27:1441-1442.
2. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999; 22:371-375.
3. McCall V, D'Agostino RB Jr, Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med 2003; 4:57-62.
4. McCall V, Perlis M, Tu X, et al. A comparison of placebo and no-treatment during a hypnotic clinical trial. Int J Clin Pharmacol Ther 2005; 43:355-359.
5. Betts TA, Alford C. Beta-blockers and sleep: A controlled trial. Eur J Clin Pharmacol 1985; 28:65-68.
6. Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: The role of ancillary properties. Circulation 1987; 75:204-212.
7. Chierichetti SM, Moise G, Galeone M, et al. Beta-blockers and psychic stress: A double-blind, placebocontrolled study of bopindolol vs lorazepam and butalbital in surgical patients. Int J Clin Pharmacol Ther Toxicol 1985; 23:510-514.
8. Gillin JC, Rapaport M, Erman MK, et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: A double-blind, 8-week clinical trial. J Clin Psychiatry 1997; 58:185-192.
9. Walsh J, Perlis M, Rosenthal M, et al. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med 2006; 2:35-41.
10. Kuntz R. Off-label prescribing of antidepressants and anxiolytics: An attorney's guide to psychoactive drugs. J Psychiatry and the Law 1998; 26:519-532.
11. Kramer S, McCall V. Off-label prescribing: 7 steps for safer, more effective treatment. Curr Psychiatr 2006; 5:15-28.
12. Dording C, Mischoulon D, Petersen T, et al. The pharmacologic management of SSRI-induced side effects: A survey of psychiatrists. Ann Clin Psychiatry 2002; 14:143-147.
13. Nierenberg A, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151:1069-1072.
14. Haffmans PMJ. The effects of trazodone on sleep disturbances included by brofaromine. Eur Psychiatry 1999; 14:167-171.
15. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol 1998; 13:191-198.
16. Montgomery I, Oswald I, Morgan K, et al. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 1983; 16:139-144.
17. Yamadera H, Nakamura S, Suzuki H, et al. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci 1998; 52:439-443.
18. Ware JC, Pittard JT. Increased deep sleep after trazodone use: A double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry 1990; 51:18-22.
19. Burns M, Hoskowitz H, Jaffe J. A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. J Clin Psychiatry 1986; 47:252-254.
20. Warrington SJ, Ankier SI, Turner P. An evaluation of possible interactions between ethanol and trazodone or amitriptyline. Br J Clin Pharmacol 1984; 18:549-557.
21. Saletu-Zyhlarz G, Abu-Bakr M, Anderer P, et al. Insomnia related to dysthymia: Polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiology 2001; 44:139-149.
22. James S, Mendelson W. The use of trazodone as a hypnotic: A critical review. J Clin Psychiatry 2004; 65:752-755.
23. DiMascio A, Weissman MM, Prusoff BA, et al. Differential symptom reduction by drugs and psychotherapy in acute depression. Arch Gen Psychiatry 1979; 36:1450-1456.
24. Kupfer DJ, Spiker DG, Coble P, et al. Amitriptyline and EEG sleep in depressed patients: I. Drug effect. Sleep 1978; 1:149-159.
25. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: A placebocontrolled, double-blind, polysomnographic study. J Clin Psychiatry 2001; 62:453-463.
26. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007; 30:1555-1561.
27. Kupfer DJ, Spiker DG, Rossi A, et al. Nortriptyline and EEG sleep in depressed patients. Biol Psychiatry 1982; 17:535-546.
28. Reynolds CF III, Buysse D, Brunner D, et al. Maintenance nortriptyline effects on electroencephalo-graphic sleep in elderly patients with recurrent major depression: Double-blind, placebo- and plasma-level-controlled evaluation. Biol Psychiatry 1997; 42:560-567.
29. Haggstram FM, Chatkin JM, Sussenbach-Vaz E, et al. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: Preliminary results. Pulm Pharmacol Ther 2006; 19:205-209.
30. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: A crossover trial. J Clin Psychiatry 2005; 66:436-443.
31. Ruigt GSF, Kemp B, Groenhout CM, et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990; 38:551-554.
32. Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: A placebo controlled, double-blind study in young healthy volunteers. Sleep 2002; 25:677-679.
33. Winokur A, DeMartinis NA III, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003; 64:1224-1229.
34. Ridout F, Meadows R, Johnsen S, et al. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol 2003; 18:261-269.
35. Cohrs S, Rodenbeck A, Guan Z, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology 2004; 174:421-429.
36. Wiegand M, Landry F, Bruckner T, et al. Quetiapine in primary insomnia: A pilot study. Psychopharmacology 2008; 196:337-338.
37. Nanda F, Singer C. Placebo-controlled trial of quetiapine for sleep disturbance in dementia and MCI [abstract]. Am J Geriatr Psychiatry 2008; 16(3)(suppl I):A126.
38. Sharpley AlL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: Evidence for blockade of central 5-HT2 C receptors in vivo. Soc Biol Psychiatry 2000; 47:468-470.
39. Sharpley AL, Attenburrow EJ, Hafizi S, et al. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry 2005; 66:450-454.
40. Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, et al. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999; 46: 141-143.
41. Muller MJ, Rossbach WMK, Roschke J, et al. Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms. Pharmacopsychiatry 2004; 37: 157-162.
42. Maixner S, Tandon R, Eiser A, et al. Effects of antipsychotic treatment on ploysomnographic measures in schizophrenia: A replication and extension. Am J Psychiatry 1998; 155:1600-1602.
43. Cohrs S, Meier A, Neumann A, et al. Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: A randomized, controlled, crossover trial of 12 healthy male subjects. J Clin Psychiatry 2005; 66:989-996.
44. Sharpley AL, Bhagwager Z, Hafizi S, et al. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry 2003; 64:192-196.
45. Mattila MAK, Salmela J, Vaananen A, et al. Midazolam vs lorazepam and placebo as hypnotic premedication before surgery. A controlled, double-blind study. Drugs Exp Clin Res 1985; 12:841-844.
46. Sanders LD, Yeomans WA, Rees J, et al. A double-blind comparison between nitrazepam, lorazepam, lormetazepam and placebo as preoperative night sedatives. Eur J Anaesthesiol 1988; 5:377-383.
47. Parrino L, Boselli M, Spaggiari MC, et al. Multidrug comparison (lorazepam, triazolam, zolpidem, and zopiclone) in situational insomnia: Polysomnographic analysis by means of the cyclic alternating pattern. Clin Neuropharmacol 1997; 20:253-263.
48. Bonnet MH, Arand DL. The use of lorazepam TID for chronic insomnia. Int Clin Psychopharmacol 1999; 14:81-89.
49. Walsh JK, Schweitzer PK, Parwatikar S. Effects of lorazepam and its withdrawal on sleep, performance, and subjective state. Clin Pharmacol Ther 1983; 34:496-500.
50. Cohn JB. Double-blind crossover comparison of triazolam and lorazepam in the posthypnotic state. J Clin Psychiatry 1984; 45:104-107.
51. Jurado JL, Fernandez-Mas R, Gernandez-Guardiola A. Effects of 1 week administration of two benzodiazepines on the sleep and early daytime performance of normal subjects. Psychopharmacology 1989; 99:91-93.
52. Kales A, Bixler EO, Soldatos C, et al. Lorazepam: Effects on sleep and withdrawal phenomena. Pharmacology 1986; 32:121-130.
53. Scharf MB, Kales A, Bixler EO, et al. Lorazepam-efficacy, side effects, and rebound phenomena. Clin Pharmacol Ther 1982; 31:175-179.
54. Kales A, Manfredi RL, Vgontzas AN, et al. Clonazepam: Sleep laboratory study of efficacy and withdrawal. J Clin Psychopharmacol 1991; 11:189-193.
55. Londborg PD, Smith WT, Glaudin V, et al. Short-term cotherapy with clonazepam and fluoxetine: Anxiety, sleep disturbance and core symptoms of depression. J Affect Disord 2000; 61:73-79.
56. Smith WT, Londborg PD, Glaudin V, et al. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? J Affect Disord 2002; 70:251-259.
57. Saletu M, Anderer P, Saletu-Zyhlarz G, et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD). Acute placebo-controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol 2001; 11:153-161.
58. Peled R, Lavie P Double-blind evaluation of clonazepam on periodic leg movements in sleep. J Neurol Neurosurg Psychiatry 1987; 50:1679-1681.
59. Kales A, Bixler EO, Vela-Bueno A, et al. Alprazolam: Effects on sleep and withdrawal phenomena. J Clin Pharmacol 1987; 27:508-515.
60. Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia 2002; 43:1493-1497.
61. Karam-Hage M, Brower K. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci 2003; 57:542-544.
62. Furieri F, Nakamura-Placios E. Gabapentin reduces alcohol consumption and craving: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68:1691-1700.
63. Arnold LM, Goldenberg D, Stanford S, et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007; 56:1336-1344.
64. Hahn K, Arendt G, Braun J, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004; 251:1260-1266.
65. Rice A, Maton S; Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 2001; 94:215-224.
66. Backonja M. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia 1990;40(suppl):S57-S59.
67. Gordh T, Stubhaug A, Jenson T, et al. Gabapentin in traumatic nerve injury pain: A randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain 2008; 138:255-266.
68. Arnold LM, Russell I, Diri E, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in pateints with fibromyalgia. J Pain 2008; 9:792-805.
69. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: Findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31:1448-1454.
70. Mease P, Russell I, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008; 35:502-514.
71. Siddall P, Cousins M, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial. Neurology 2006; 67:1792-1800.
72. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005; 28:187-193.
73. Bowden CL, Swann A, Calabrese J, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Pyshciatry 2006; 67: 1501-1510.
74. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004; 20:1979-1991.
75. Roth T, Soubrane C, Titeux L, et al. Eficacy and safety of zolpidem-MR: A double-blind, placebocontrolled study in adults with primary insomnia. Sleep Med 2006; 7:397-406.
76. Zammit GK, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007; 3:495-504.